Conference Proceeding

Immunotherapy of Advanced stage invariably Drugs Resistant Cancers

Dr. G. P. Talwar ,
Founder and Director, National Institute of Immunlogy, India

Cancer is accounting for increasing number of deaths in all countries.

G. P. Talwar is a medical researcher working in the area of vaccines and immunocontraception. He received BSc (Hons) and MSc (Tech) degrees from the University of Punjab; DSc from Sorbonne working at the Institute Pasteur, Paris and DSc (hc) from Bundhelkhand University .He was Alexander von Humboldt Postdoctoral Fellow at Tübingen, Stuttgart and Munchen. He joined as Associate Professor of Biochemistry in the newly created All India Institute of Medical Sciences (AIIMS), New Delhi and also worked there as Professor and Head. He was Head, ICMR-WHO Research and Training Centre in Immunology for India and South East Asia (1972–91). He was the first Director of the National Institute of Immunology (NII). He was Professor of Eminence and Senior Consultant, International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi and Director Research, Talwar Research Foundation, New Delhi, India.

Cancer is accounting for increasing number of deaths in all countries. If detected at an early stage, it can be surgically removed. Radiations and a fairly large number of drugs are available to take care of most cancers. However a stage arrives in many cancers that residual Drugs-resistant cancer emerges. It is metastasized, hence not removable surgically, nor controllable by radiations. At this advanced stage, many cancers start expressing ectopically the embryonic hormone hCG. Data will be presented to show that Monoclonal antibodies against hCG can be employed to kill cancer cells, such as those of lung cancer. Some cancer cells such as those of Molt-4 lymphoblastic leukemia express hCG, but are not killed by anti-hCG antibodies alone or in presence of Complement. These cancer cells are completely eliminated by using the antibody conjugated to Curcumin, a totally safe compound. Therapeutic antibodies are expensive for repeated intake. These require backing by a Vaccine evoking potent anti-hCG response. We have developed a highly immunogenic recombinant Vaccine against hCG, which is amenable to industrial production for unlimited supply. Also a highly useful and already approved Vaccine by DCGI and USFDA is available. It is based on Mycobacterium indicus pranii (MIP), which has both preventive and therapeutic action against Myelomas and other cancers and is being used by Clinicians in India as djunct to other therapies for cancers. It is a potent invigorator of both humoral and cellular immune response.

Published: 11 May 2017